drugset / Trial / NCT03688802

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802

Phase 2 Completed 18 enrolled Oyster Point Pharma, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult subjects with DED.

Timeline

Start
2018-09-25
Primary completion
2019-09-30
Completion
2019-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Varenicline Small molecule 0.06 mg Intranasal

Indications